Kestra Advisory Services’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kestra Advisory Services’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,636	Closed	-$45.9K	–	2064
2022 Q4	$45.9K	Buy	+10,636	New	+$61.7K	﹤0.01%	2184
2022 Q3	–	Sell	-583,834	Closed	-$5.87M	–	2111
2022 Q2	$5.87M	Buy	+583,834	New	+$6.53M	0.06%	328

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kestra Advisory Services's AUPH Position: Q1 2023 in Review

Kestra Advisory Services sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 10,636 shares — an estimated $45.9K sold.

Kestra Advisory Services first reported a position in AUPH in Q2 2022 and held it in 2 quarters. The position peaked at $5.87M in Q2 2022. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

Kestra Advisory Services reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Kestra Advisory Services sold 10,636 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $45.9K.
Kestra Advisory Services first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Kestra Advisory Services's Aurinia Pharmaceuticals position peaked at $5.87M in Q2 2022.
186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on Kestra Advisory Services's 13F filing for Q1 2023, filed 12 May 2023.